Paul Drury

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

A Keech, R. John Simes, Philip J. Barter et al. · The Lancet · 2005 · 3.2K citations

Diabetes Management, Cardiovascular Disease, Health Policy +9

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy

Tomás Berl, Lawrence G. Hunsicker, Julia B. Lewis et al. · Annals of Internal Medicine · 2003 · 397 citations

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

Robert C. Atkins, Esther M. Briganti, Julia B. Lewis et al. · American Journal of Kidney Diseases · 2005 · 366 citations

Glomerular Disease, Glomerulonephritis, Urology +11